Mohammed T Ali1, Evin Yucel1, Souhila Bouras1, Lin Wang1, Hong-Wen Fei1, Elkan F Halpern2, Marielle Scherrer-Crosbie3. 1. Cardiac Ultrasound Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Institute for Technology Assessment, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Cardiac Ultrasound Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: marielle@crosbie.com.
Abstract
BACKGROUND: Anthracycline-induced symptomatic heart failure is often irreversible, underlining the usefulness of pretreatment risk assessment. Global longitudinal strain (GLS) before or after chemotherapy is associated with a later decrease in left ventricular ejection fraction (LVEF); however, whether prechemotherapy GLS is associated with symptomatic heart failure and cardiac death in patients treated with anthracyclines is unknown. METHODS: Patients with hematologic cancers treated with anthracyclines who underwent prechemotherapy echocardiography between November 2006 and June 2011 were retrospectively recruited. Basic demographic data, end-diastolic and end-systolic left ventricular volumes, LVEF, and GLS were measured. Clinical cardiac events (CEs) were defined as cardiac death or symptomatic heart failure. The association of prechemotherapy parameters with CEs was analyzed using proportional hazard analysis. RESULTS: Over a median follow-up period of 1,593 days (range, 13-2,891 days) after the start of chemotherapy, 28 of 450 patients (6%) experienced CEs. Prechemotherapy LVEF and GLS were lower in patients with CEs compared with those without CEs (58 ± 10% vs 62 ± 7% [P = .005] and -15.0 ± 2.8% vs -19.7 ± 2.7% [P < .0001], respectively). Diabetes (hazard ratio [HR], 7.06; P < .0001), hypertension (HR, 2.22; P = .04), LVEF (HR, 0.93; P = .005), and GLS (HR, 1.47; P < .0001) were associated with CEs. After controlling for clinical variables, prechemotherapy GLS remained independently associated with CEs (P < .0001). GLS less than the absolute value of -17.5% was found in 105 patients (23%) and was associated with a sixfold increase in CEs (P < .0001). CONCLUSIONS: Prechemotherapy GLS is an effective tool to stratify patients at high risk for CEs after anthracycline therapy and may help tailor treatments to decrease anthracycline-induced cardiotoxicity.
BACKGROUND:Anthracycline-induced symptomatic heart failure is often irreversible, underlining the usefulness of pretreatment risk assessment. Global longitudinal strain (GLS) before or after chemotherapy is associated with a later decrease in left ventricular ejection fraction (LVEF); however, whether prechemotherapy GLS is associated with symptomatic heart failure and cardiac death in patients treated with anthracyclines is unknown. METHODS:Patients with hematologic cancers treated with anthracyclines who underwent prechemotherapy echocardiography between November 2006 and June 2011 were retrospectively recruited. Basic demographic data, end-diastolic and end-systolic left ventricular volumes, LVEF, and GLS were measured. Clinical cardiac events (CEs) were defined as cardiac death or symptomatic heart failure. The association of prechemotherapy parameters with CEs was analyzed using proportional hazard analysis. RESULTS: Over a median follow-up period of 1,593 days (range, 13-2,891 days) after the start of chemotherapy, 28 of 450 patients (6%) experienced CEs. Prechemotherapy LVEF and GLS were lower in patients with CEs compared with those without CEs (58 ± 10% vs 62 ± 7% [P = .005] and -15.0 ± 2.8% vs -19.7 ± 2.7% [P < .0001], respectively). Diabetes (hazard ratio [HR], 7.06; P < .0001), hypertension (HR, 2.22; P = .04), LVEF (HR, 0.93; P = .005), and GLS (HR, 1.47; P < .0001) were associated with CEs. After controlling for clinical variables, prechemotherapy GLS remained independently associated with CEs (P < .0001). GLS less than the absolute value of -17.5% was found in 105 patients (23%) and was associated with a sixfold increase in CEs (P < .0001). CONCLUSIONS: Prechemotherapy GLS is an effective tool to stratify patients at high risk for CEs after anthracycline therapy and may help tailor treatments to decrease anthracycline-induced cardiotoxicity.
Authors: Ali Agha; Abdulrazzak Zarifa; Peter Kim; Cezar Iliescu; Greg Gladish; Saamir Hassan; Nicolas Palaskas; Jean B Durand; Yang Lu; Juan Lopez-Mattei Journal: Methodist Debakey Cardiovasc J Date: 2019 Oct-Dec
Authors: Gregory J Cascino; Woo Bin Voss; Jonathan Canaani; Nicholas Furiasse; Alfred Rademaker; Bonnie Ky; Selina Luger; Jessica K Altman; James M Foran; Mark R Litzow; Martin S Tallman; Vera Rigolin; Nausheen Akhter Journal: Echocardiography Date: 2019-11-08 Impact factor: 1.724
Authors: Diego Medvedofsky; Francesco Maffessanti; Lynn Weinert; David M Tehrani; Akhil Narang; Karima Addetia; Anuj Mediratta; Stephanie A Besser; Elad Maor; Amit R Patel; Kirk T Spencer; Victor Mor-Avi; Roberto M Lang Journal: JACC Cardiovasc Imaging Date: 2017-11-15
Authors: Jakob Park; Yekaterina Kim; Jason Pereira; Kerrilynn C Hennessey; Kamil F Faridi; Robert L McNamara; Eric J Velazquez; David J Hur; Lissa Sugeng; Vratika Agarwal Journal: Am Heart J Plus Date: 2021-06-01
Authors: Nina Rosa Neuendorff; Kah Poh Loh; Alice S Mims; Konstantinos Christofyllakis; Wee-Kheng Soo; Bediha Bölükbasi; Carlos Oñoro-Algar; William G Hundley; Heidi D Klepin Journal: Blood Adv Date: 2020-02-25